Eli Lilly CEO Lechleiter Urges Speeded Clinical-Trial Process in China
This article was originally published in PharmAsia News
Executive Summary
Eli Lilly CEO John Lechleiter complained that China's drug-approval process takes eight year more than other major countries, a disparity that needs to be closed.